Work

Phase 3 clinical trial on the prevention of maternal-fetal cytomegalovirus transmission with specific hyperimmunoglobulin could not demonstrate efficacy

Year: 2025

Type: article

Abstract: Primary cytomegalovirus (CMV) infection in pregnancy, followed by a maternal-fetal transmission is a major cause of developmental disorders of newborns worldwide. The efficacy of passive immunization with specific hyperimmunoglobulin (CMVIG) remains equivocal. In previous studies, the dosage, timing, and frequency of CMVIG administration differed considerably. In a previous publication, we documented a maternal-fetal transmission rate of 6.5% (10 out of 153 cases [95% confidence interval 3.2–11.7]) for an application of 200 U/kg body weight (BW) of CMVIG every 2 weeks.

Source: American Journal of Obstetrics and Gynecology

DOI: 10.1016/j.ajog.2025.07.050

Authors: Karl Oliver Kagan, Martin Enders, Silke Aigner, Joachim Schütze, Stephan Lentze, Christiane Staiger

Institutions: Universitätsklinikum Tübingen, Universitäts Frauenklinik, Biotest (Germany)

Language: English

Topic: Cytomegalovirus and herpesvirus research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,410